Connection

William Creasman to Antineoplastic Combined Chemotherapy Protocols

This is a "connection" page, showing publications William Creasman has written about Antineoplastic Combined Chemotherapy Protocols.
  1. Treating Locally Advanced Cervical Cancer With Concurrent Chemoradiation Without Brachytherapy in Low-resource Countries. Am J Clin Oncol. 2016 Feb; 39(1):92-7.
    View in: PubMed
    Score: 0.415
  2. Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2016 Dec; 143(3):511-515.
    View in: PubMed
    Score: 0.109
  3. Neoadjuvant chemotherapy with vincristine and cisplatin followed by radical hysterectomy and pelvic lymphadenectomy for FIGO stage IB bulky cervical cancer: a Gynecologic Oncology Group pilot study. Gynecol Oncol. 1995 Jun; 57(3):412-6.
    View in: PubMed
    Score: 0.099
  4. A randomized trial of cyclophosphamide, doxorubicin, and cisplatin with or without bacillus Calmette-Guerin in patients with suboptimal stage III and IV ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 1990 Dec; 39(3):239-43.
    View in: PubMed
    Score: 0.072
  5. Treatment of ("bulky") stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the gynecologic oncology group. Gynecol Oncol. 2007 Aug; 106(2):362-9.
    View in: PubMed
    Score: 0.057
  6. A VP16-213- and cisplatin-containing regimen for treatment of refractory ovarian germ cell malignancies. Am J Obstet Gynecol. 1984 Dec 15; 150(8):927-31.
    View in: PubMed
    Score: 0.048
  7. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017 Oct 07; 390(10103):1654-1663.
    View in: PubMed
    Score: 0.029
  8. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 1995 Jul; 13(7):1589-99.
    View in: PubMed
    Score: 0.025
  9. Second-look laparotomy in ovarian cancer. Gynecol Oncol. 1994 Dec; 55(3 Pt 2):S122-7.
    View in: PubMed
    Score: 0.024
  10. Intraperitoneal chromic phosphate P 32 as salvage therapy for persistent carcinoma of the ovary after surgical restaging. Am J Obstet Gynecol. 1987 May; 156(5):1153-8.
    View in: PubMed
    Score: 0.014
  11. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer. 1986 May 01; 57(9):1725-30.
    View in: PubMed
    Score: 0.013
  12. Assessment of the contemporary management of germ cell malignancies of the ovary. Am J Obstet Gynecol. 1985 Dec 15; 153(8):828-34.
    View in: PubMed
    Score: 0.013
  13. Vincristine, dactinomycin, and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary. A Gynecologic Oncology Group Study (a final report). Cancer. 1985 Jul 15; 56(2):243-8.
    View in: PubMed
    Score: 0.012
  14. Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group). Cancer. 1985 Apr 15; 55(8):1648-53.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.